
The study assessed the safety and efficacy of using mesenchymal stromal cells (MSCs) and their derived extracellular vesicles (EVs) as a treatment for severe COVID-19 patients with acute respiratory distress syndrome (ARDS). It included 43 patients divided into three groups: MSC alone, MSC plus EV, and a control group. The results showed that MSC infusion decreased inflammatory cytokines and markers such as IL-6, TNF-α, IFN-γ, and CRP. Mortality rates were lower in the MSC-treated groups compared to the control group. The study suggests that MSCs and their EVs may effectively reduce inflammation in COVID-19 patients without serious adverse effects.
Like
Save
Share